NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Life Biosciences

Life Biosciences

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://www.lifebiosciences.com/

Last Round

Series D

Apr 8, 2026

Est. Valuation

$500M

Total Funding Raised

$212M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Life Biosciences is a biotechnology company that develops drug therapies aimed at enhancing the quality of life for aging individuals by addressing the systemic health decline associated with aging and combating age-related diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapypartial reprogrammingage-reversal therapycellular rejuvenationanti-agingpartial epigenetic reprogrammingPERoptic neuropathiesglaucoma treatmentlongevity biotechclinical-stage biotechcell reset therapyregenerative medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Life Biosciences Comparables

Compare Life Biosciences with similar companies based on industry and business-model similarity.

Life Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
NewLimit
85%
Cambrian Bio
81%
Turn Biotechnologies
81%

Life Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DApr 8, 2026
Series CJan 5, 2022
Series BJan 15, 2019

Life Biosciences Investors

Notable investors and investment history

Life Biosciences investors
InvestorRounds
The Longevity FundSeries C
McKenny-McFarlane CapitalSeries C
The Venture CollectiveSeries C
Alpha Wave GlobalSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 16, 2026

    Monthly visitors grew 92% MoM.

  • Apr 9, 2026

    Developing Partial Epigenetic Reprogramming (PER) platform.

Life Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Life Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Life Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range27
Year Founded2017
Last FundingApr 8, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.